• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10 Orthopedic Device Firms
    • Buyers' Guide
    • Events
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10 Orthopedic Device Firms
  • Buyers' Guide
  • Events
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    Top Features
    From Nitinol to Nanotubes: A Materials Science Roundtable

    In Good Repair: Trauma Technologies Under Review

    Anxious Undertones: A Review of 2019

    Automated Analysis Advantages for Part Validation

    Tried and True Metalworking
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy

    Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand

    TriMed Closes Out FDA Warning Letter

    FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System

    OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy

    TriMed Closes Out FDA Warning Letter

    Sounding Board: Looking Back at 2019 and Gazing at 2020

    OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application

    Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Sounding Board: Looking Back at 2019 and Gazing at 2020

    Molybdenum-Rhenium Biomaterial: Something ‘MoRe’?

    New Exoskeleton Shoulders Rehab Burden for Stroke Patients

    Repairing Knee Cartilage Defects with the Patient's Own Cells

    Compamed 2019 Preview Report
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    Hammill Medical

    Tecomet

    NN Life Sciences

    Teleflex Medical OEM

    Orchid Orthopedic Solutions
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10 Orthopedic Device Firms
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Breaking News

    Five Medical Device Risk Management Myths … And How to Avoid Them

    02.01.11

    Elvis lives. The moon landing was staged in a Hollywood studio. Brett Favre is too old to play pro football. Legions of believers tenaciously have held these views, which have proven to be akin to urban myths. Before we snicker at those harboring such beliefs, we should consider that some medical device industry professionals likewise embrace their own misconceptions.

    These myths, though, can undermine a company’s risk management program and wreak financial havoc. Let us, therefore, look at five common risk management myths in an effort to sidestep them.


    MYTH #1


    “Insurance is a commodity.”


    Buyers at many medical device firms often think that all insurance is alike; a policy is a policy is a policy. Admittedly, insurance is not a high cache product. At cocktail parties, no one boasts, “I just bought a AAA+ rated insurance policy!” In our personal lives, the advertising theme drummed into consumers is low cost, the best price and the cheapest quote. A prominent personal lines insurer boasts that 15 minutes could save you 15 percent or more off the current cost of coverage.


    In truth, though, insurance is no more a commodity than stocks are a commodity. You can buy stocks in highly leveraged,financially shaky companies. Alternatively, you can buy blue chip securities. Thedegree of financial risk often is inverselyrelated to the price. Likewise, insurance protection is not a commodity. Just like in stocks, there are meaningful differentiators from one insurance company or policy to another. These differences, aside from price, may include:


    • The insurer’s financial healthand stability;


    • The insurer’s claim-paying history and tendencies (policyholder-oriented or hard-nosed in contesting everything?);


    • Scope of coverage—narrow or broad, bland/generic or tailored to a firm in the medical technology realm?;


    • Post-loss services: loss control, risk management, education services, etc.; and


    • Ease of doing business.

     

    Moral: Not all insurance companies—or insurance policies—are created equal. Flour, eggs or 20 lb. bags of sugar from Costco may be commodities. Insurance, however, is not.


    MYTH #2


    “If I forego insurance, plaintiff lawyers cannot touch me.”


    When injured patients and plaintiff lawyers sue device firms, they have no way of knowing at that point if the defendant has liability insurance or not. They may assume that some kind of insurance exists and that any prudent business has liability protection. So, they file the lawsuit. Uncertainty over whether or not insurance exists is no deterrent to filing lawsuits.
    Typically, only later in the lawsuit’s “discovery” or fact-finding phase does the issue arise.


    Interrogatories are written questions that each side serves on the other, requiring written responses within a certain time frame. Usually, one interrogatory question is, “Please list each and every liability insurance policy to which this claim applies, including the name of the insurance company, policy number and policy limits.” At this point, the existence or non-existence of insurance will surface. If the device firm company has no insurance, it is unlikely that the injured patient or lawyer will just drop the claim. More probably, they will see that as the manufacturer’s problem – how to come up with the money to pay defense lawyers and any settlement or jury award.


    Bottom line: Forgoing insurance coverage is unlikely to cause patients from asserting claims or lawyers from filing lawsuits. The presence of insurance coverage is more a result of lawsuits, not the cause of them.


    MYTH #3


    “Why invest in loss prevention? That’s why I buy insurance.”


    This is what insurance folks call morale hazard. Morale hazard is an attitude of indifference toward loss due to insurance cushioning some of the financial consequences of loss. The best accounts, however, blend risk management with insurance as a one-two punch against financial uncertainty. Insurance companies—throughtheir underwriting processes—often grant the most favorable coverage terms to the best risks.


    One way to qualify as a good risk is to be loss-free, i.e., having no claims. Another way is to show that the company has a strong risk management program that boosts product quality and prevents malfunctions and defects. This may include tight legal review of all warnings, labels, promotional and marketing materials. It may encompass state-of-the-art manufacturing and design. It may embrace a track record of spotless U.S. Food and Drug Administration (FDA) compliance and an absence of recalls, warning letters or 483s. It may reflect a documented history of responding promptly and appropriately to FDA concerns. Strong loss control programs and insurance are complementary features of sound risk management.


    MYTH #4


    “Any claims I get will likely be defeated due to the fact that adverse outcomes are due touser error.”


    Device professionals take understandable pride of ownership, regardless of whether their companies make infusion pumps, motorized scooters or disposable tubing. There can develop a mentality that “our products are idiot-proof—unless you are a genuine idiot.” Firms may cling to the notion that only a dummy could fail to use the device in an intended matter. Ergo, the only way a malfunction could occur would be from user error. The user could be a nurse, a patient or even a physician.


    What this theory ignores is the reality that, in medical product litigation, user error defenses typically evoke an allegation of failure to warn. Plaintiffs likely will assert that the device manufacturer failed to adequately and properly label the device, failed to warn about potential misuse of the device and consequences thereof, and failed to adequately instruct or train users in how the device should be safely used. Plaintiffs also may counter that some types of product misuse reasonably were foreseeable by the device company and were avoidable through proper training, better warnings or alternative designs. Therefore, “user error” is not an airtight defense. Instead, it throws the focus back on to the Watergate-type question, “What did the manufacturer know, and when did it know it?”


    Further, asserting user error as a claim defense also often can be the risk management equivalent of cutting off your nose to spite your face. Device firms’ “users” are their customers: doctors, nurses and other healthcare personnel. These are often the people who buy medical devices or who drive purchasing decisions. In business, blaming your customers is not a sound strategy. Business aside, in litigation, finger-pointing at customers can be disastrous. Plaintiff attorneys prefer situations where the device manufacturer and doctor each blame the other. ”Divide and conquer” strategies can create situations where the plaintiffs do not even have to prove their case; the co-defendants in the lawsuit are doing such a great job for them. After hearing the conflicting testimony, was it a defect or a user error that caused the patient’s injury? Jurors may figure both had culpability and award

    damages accordingly.


    The moral is not that device companies always should forgo “user error” defenses or always “take the fall” in cases of clear product misuse. It is to say that “user error” has risks from a claim defense standpoint and can win the litigation battle but lose the business war. Use it selectively.


    MYTH #5


    “The “Federal preemption”defense will protect me from product liability claims.”


    In the wake of the Supreme Court’s early 2008 decision in Riegel v. Medtronic, many device firms thereafter thought that FDA approval would bar or “preempt” state tort claims alleging product defects. Euphoria was premature, though. First, Riegel only applied to Class III devices that had gone through the pre-market approval (PMA) process. Most devices are not PMA devices and thus cannot count on Riegel preemption.Most claims—suits against non-PMA devices—will still survive, as will claims for manufacturing defects. Plaintiffs also can sue makers of devices not conforming to the specifications or safety processes approved during PMA review. Riegel was a good start, but no panacea for medical device firms managing product liability risk.


    Elvis has left the building permanently and is not coming back.The Apollo moon landing was real. Bret Favre may unretire yet again. Medical device firms should be aware of these risk management fallacies and avoid them in structuring sound risk management programs that can protect their firms’ financial health, brand and reputation.

     

    Kevin Quinley is Vice President, Risk Management Services for Berkley Life Sciences, LLC. Berkley Life Sciences LLC is a provider of insurance for the life science industry. The views expressed here do not constitute legal advice, are those of the author alone and do not necessarily reflect those of Berkley Life Sciences or its customers. You can reach Kevin at kquinley@berkleyls.com.

    Related Breaking News

    • MIS/Robotics | Spine/Neurology
      Zimmer Biomet Recalls ROSA Brain 3.0 Robotic Surgery System

      Zimmer Biomet Recalls ROSA Brain 3.0 Robotic Surgery System

      The device is being recalled due to a software issue that incorrectly positions the robotic arm.
      U.S. Food and Drug Administration 11.08.19

    • Biocompatibility & Testing | Software & Quality
      AAOS: GE Additive Launches Orthopedic Validation Consultancy

      AAOS: GE Additive Launches Orthopedic Validation Consultancy

      Q&A with Anders Ingvarsson, product manager of Arcam EBM detailing release of a new solution at the AAOS 2018 annual meeting.
      GE Additive 03.09.18

    • DJO Notifies Individuals of Potential Breach of Personal Information

      DJO Notifies Individuals of Potential Breach of Personal Information

      Affects those who received a DJO product from a Las Vegas hospital between July 17—Oct. 16, 2017.
      Business Wire 01.09.18


    • Large Joint
      Stryker Hip Lawsuits Move Forward in New Jersey

      Stryker Hip Lawsuits Move Forward in New Jersey

      Issuance of 4th Case Management Order governing LFIT V40 Femoral Head claims, Bernstein Liebhard LLP reported.
      PR Newswire 11.27.17

    • Spine/Neurology | Trauma/Sports
      NASS News: New Standard Supports High-Strength Alloy for Surgical Implants

      NASS News: New Standard Supports High-Strength Alloy for Surgical Implants

      The new alloy does not contain elements such as nickel, chromium, or cobalt.
      ASTM International 10.13.17

    • Coatings/Surface Modification | Materials
      Scaffold Breakthrough May Banish Implant Infections

      Scaffold Breakthrough May Banish Implant Infections

      Cross-linked collagen scaffold marks an important step forward against a major health problem.
      IOP Publishing 06.20.17


    • Large Joint
      Reducing Infections in Total Hip & Knee Replacement Patients

      Reducing Infections in Total Hip & Knee Replacement Patients

      Rheumatologists & orthopedic surgeons collaborate to provide new recommendations for perioperative management.
      American College of Rheumatology (ACR) 06.19.17

    • Spine/Neurology
      Zimmer Biomet Recalls Implantable Spinal Fusion Stimulators

      Zimmer Biomet Recalls Implantable Spinal Fusion Stimulators

      The devices were recalled due to potential of harmful chemicals which may be toxic to tissues and organs.
      U.S. Food and Drug Administration 06.02.17

    • Large Joint
      Opioid Use Pre-TKR Results in Worse Pain Outcomes

      Opioid Use Pre-TKR Results in Worse Pain Outcomes

      Patients taking opioids pre-TKR experienced 9 percent less pain reduction 6 months post-surgery compared to those who didn't.
      Brigham and Womens Hospital 05.19.17


    • Large Joint
      Patients 11x Less Likely to Take Opioids at Last Follow-Up Using iFuse Implant

      Patients 11x Less Likely to Take Opioids at Last Follow-Up Using iFuse Implant

      Study showed reduction in opioid use in patients with chronic SI joint pain.
      PR Newswire 05.01.17

    • Large Joint | Trauma/Sports
      AAOS: Why Some ACL Surgeries Fail

      AAOS: Why Some ACL Surgeries Fail

      Common surgery for helping active people get their mobility back can create problems if the ligament re-tears.
      Michigan Medicine - University of Michigan 03.23.17

    • Large Joint | Spine/Neurology
      AAOS: Degree of Spinal Deformity Affects Hip Replacement Surgery

      AAOS: Degree of Spinal Deformity Affects Hip Replacement Surgery

      Until now, no studies of the hip-spine relationship have focused on patients with sagittal spinal deformity.
      NYU Langone Medical Center/New York University School of Medicine 03.17.17

    • Large Joint
      AAOS: Smoking Cessation Programs Benefit Patients Prior to Joint Replacements

      AAOS: Smoking Cessation Programs Benefit Patients Prior to Joint Replacements

      Smokers who undergo a total joint replacements have a 50 percent increased risk of experiencing complications during surgery.
      NYU Langone Medical Center/New York University School of Medicine 03.16.17

    • Biologics | Spine/Neurology
      AAOS: Caution Against Bone Morphogenetic Proteins in Children

      AAOS: Caution Against Bone Morphogenetic Proteins in Children's Spine Surgery

      BMP is frequently used off-label for pediatric spinal fusions.
      Hospital for Special Surgery 03.15.17

    • Large Joint
      Zimmer Biomet Recalls Comprehensive Reverse Shoulder Due to High Fracture Rate

      Zimmer Biomet Recalls Comprehensive Reverse Shoulder Due to High Fracture Rate

      The devices are fracturing at a higher rate than is stated in the labeling.
      U.S. Food and Drug Administration 03.01.17


    Breaking News
    • FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy
    • Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand
    • TriMed Closes Out FDA Warning Letter
    • FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System
    • OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application
    View Breaking News >
    CURRENT ISSUE

    November/December 2019

    • From Nitinol to Nanotubes: A Materials Science Roundtable
    • In Good Repair: Trauma Technologies Under Review
    • Anxious Undertones: A Review of 2019
    • View More >
    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Deerland Obtains Certification from Australia’s Therapeutic Goods Administration
    OptiMSM Shown to Improve Hair & Nail Appearance and Condition
    DCC Acquires Contract Manufacturer Ion Laboratories
    Coatings World

    Latest Breaking News From Coatings World

    Arkema: Bostik Acquires Danish Company LIP
    Axalta Adds New Epoxy Primer to Tufcote Liquid Industrial Coatings Portfolio
    Chromaflo Technologies Promotes Sergio Duenas to Country Manager of Mexico
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs World's First Single-Use Duodenoscope
    Dr. Stephen Hahn Confirmed as New FDA Leader
    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Sanofi Awarded $226M by US Gov't for Pandemic Influenza Preparedness
    Amgen Selects Location For R&D Facility
    Arctoris Opens Oxford R&D Facility
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Time Features 5 Best Beauty Inventions
    CES 2020 Preview - Innovation Award Honorees in Health & Wellness
    Prada & L’Oréal Sign Long-Term Licensing Deal
    Happi

    Latest Breaking News From Happi

    Cosmetic Assessments Revealed at CIR Panel
    T-Boz Launches CBD Line
    DRF and Flowerkist Develop CBD Range
    Ink World

    Latest Breaking News From Ink World

    Ripon Printers Adds Ricoh Pro C9210
    LogoJet Opens Bogota, Colombia Office
    Canon Solutions America Powers University of Notre Dame Athletics' Printing Capabilities
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    GSE products provide quality assurance for Pharmalabel
    Luminer promotes Heather Bookman to prepress manager
    Materials Exchange launches to solve excess inventory issue
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    DuPont to Acquire Osmosis Specialist
    Nice-Pak to Expand in Indiana
    Hospeco Launches Compact Fem Hy Dispenser
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy
    Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand
    TriMed Closes Out FDA Warning Letter
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    3D Printing Materials Market to Grow at 23.9% CAGR Through 2025: GVR
    Kyocera, TactoTek Collaborate on Injection Molded Structural Electronics Solutions
    Toray Opens R&D Innovation Center for the Future

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.